Clinical trial
A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors
NCT04233060 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors
- Lead sponsor
- CStone Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 10, 2020
- Completion date
- February 17, 2021
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor